Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Melanoma 13 Colorectal Neoplasms 5 Neoplasm Metastasis 4 Neoplasms 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Solid Tumors Harboring a BRAF V600 Mutation 1 Skin Neoplasms 1 Skin Diseases 1 Pancreatic Neoplasms 1 Lymphatic Metastasis 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Astrocytoma 1 Advanced BRAF Mutant Cancers 1

Interventions

Temozolomide 115 Bevacizumab 72 Radiotherapy 52 Radiation 23 Erlotinib Hydrochloride 13 Lomustine 12 pembrolizumab 11 Magnetic Resonance Spectroscopy 11 Vorinostat 10 Nivolumab 10 Surgical Procedures, Operative 9 Irinotecan 9 Sorafenib 8 Radiotherapy, Intensity-Modulated 8 Radiotherapy, Conformal 7 Immunoglobulin G 7 Everolimus 7 Drug Therapy 7 Disulfides 7 Radiosurgery 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Carmustine 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Sirolimus 5 Cilengitide 5 veliparib 4 veledimex 4 temsirolimus 4 selinexor 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Glioblastoma × encorafenib × Clear all

NCT03973918 2024-10-31

BRAF

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated

5 enrolled 15 charts

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡